

Supplementary Information for:



**Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine induces
equivalent preclinical antibody titers and viral neutralization to
recovered COVID-19 patients**

Paul F. McKay¹, Kai Hu¹, Anna K. Blakney¹, Karnyart Samnuan¹, Clément R. Bouton¹, Paul Rogers¹, Krunal Polra¹, Paulo J.C. Lin², Christopher Barbosa², Ying Tam², Robin J. Shattock^{1,*}


¹ Department of Infectious Diseases, Imperial College London, Norfolk Place, London, United Kingdom W2 1PG

²Acuitas Therapeutics, Vancouver, British Columbia, Canada, V6T 1Z3


*Corresponding author. Email: r.shattock@imperial.ac.uk




Supplementary Figure 1. Flow cytometry of HEK293T.17 cells transfected with vaccine expressing membrane bound SARS-CoV-2 spike protein.




Supplementary Figure 2. Th1/Th2 skew in response to SARS-CoV-2 saRNA LNP vaccine. a) IgG1 and IgG2a responses in mice vaccinated with doses of LNP-formulated saRNA ranging from 0.01-10 µg of saRNA with n=7, b) Th1/Th2 skewing responses in mice vaccinated with doses of LNP-formulated saRNA ranging from 0.01-10 µg of saRNA with n=7, and 10 µg of electroporated pDNA (EP pDNA) with n=8.



Supplementary Figure 3. Pseudotyped virus neutralization of sera from BALB/c mice vaccinated with LNP formulations and human patients after recovery from COVID-19.



Supplementary Figure 4. Cytokine response of re-stimulated splenocytes of vaccinated mice with recombinant SARS-CoV-2 protein.



Supplementary Figure 5. Cytokine response in the sera of mice 4 hours after vaccination with SARS-CoV-2 LNP vaccine.